Neutral
TSHA Maintained by B of A Securities -- Price Target Raised to $10.00
B of A Securities analyst Tazeen Ahmad maintained a 'Buy' rating on Taysha Gene Therapies (TSHA), increasing the price target from $9.00 to $10.00, su...